Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (566)	4/25/2001 9:41:05 AM
From: nigel bates	Read Replies (1) \| Respond to of 1784

April 25, 2001-- Amersham Pharmacia Biotech today announced the introduction of the TempliPhi(TM) template amplification kit, an innovative new product that will significantly reduce the time and cost of DNA sequencing by improving the efficiency of DNA sample, or template, preparation. Amersham Pharmacia Biotech is a leading provider of instruments and reagents for DNA sequencing with products such as the MegaBACE(TM) DNA Analysis System and DYEnamic(TM) ET Terminator kits. The introduction of TempliPhi expands Amersham Pharmacia Biotech's genomics offering into the sequencing template preparation market. Preparing samples for sequencing is one of the most time-consuming steps in the process. Current template preparation methods rely on a labor-intensive, multi-step procedure that can take up to 24 hours and produce DNA of varying quality and quantity. Using a technology called Rolling Circle Amplification (RCA) and a DNA polymerase licensed exclusively to Amersham Pharmacia Biotech, the new TempliPhi method provides a cost-effective alternative to growing bacteria and purifying the template prior to sequencing. TempliPhi allows researchers to produce ready-to-use DNA of a consistent quality and quantity in just four hours, using two easily automated steps. ``With the worldwide growth in sequencing, there is an increasing demand for products that reduce the time and cost of sequencing sample preparation.'' said Mark Sutherland, Vice President for Genomics, Amersham Pharmacia Biotech. ``We believe TempliPhi provides researchers with a way to meet the demands of today's high-throughput sequencing instruments and that it will significantly advance template preparation.'' (edit) Molecular Staging Inc. is a private, life sciences tool company developing a portfolio of technologies for the detection and measurement of proteins and nucleic acids across a broad range of applications, including proteomics, genomics, pharmacogenomics and diagnostics. MSI's core technology is Rolling Circle Amplification Technology (RCAT(TM)), an isothermal amplification process for detecting and measuring all classes of biomolecules including protein, DNA, and RNA. RCAT(TM) has significant advantages in dynamic range, scalability, sensitivity, multiplexing and flexibility over older methods, such as PCR. RCAT(TM) is the only molecular amplification method that allows target recognition, signal amplification, and detection all to be performed directly on a microarray. The technology is compatible with many existing instrument platforms and is ideally suited for multiplexing assays in liquid and solid phase and direct amplification in cells and tissues. MSI is located in New Haven, Connecticut. Additional information about MSI can be found at molecularstaging.com.